MindMed is one of the first publicly-listed companies racing to develop blockbuster psychedelic medicine to treat mental health problems.
MindMed is studying the potential therapeutic uses of LSD
MindMed and the University Hospital Basel’s Liechti Lab in Switzerland are set to start the Phase 1 clinical trial of a combined MDMA-LSD in the fourth quarter of this year. They are testing the possibility that the combination will produce positive acute effects when compared to the drugs on their own. MMDA could reduce some of the negative mood effects of LSD and make the patient more comfortable during psychedelic-assisted therapy.
On Thursday, MindMed announced that it is also collaborating with the University Hospital Basel’s Liechti Lab in the research and development (R&D) of psilocybin. They are interested in understanding how psilocybin or LSD affects a person’s consciousness.
Dr. Matthias Liechti, one of the world’s leaders in psychedelics pharmacology and clinical research at the University Hospital Basel, is conducting both studies.
